Malignant Neoplasms of Female Genital Organs
12
1
6
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
16.7%
2 terminated out of 12 trials
33.3%
-53.2% vs benchmark
17%
2 trials in Phase 3/4
200%
2 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (12)
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Selumetinib and Olaparib in Solid Tumors
Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley
Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
Neuromuscular Blockade on Shoulder Pain of Elderly
Pneumoperitoneum Management With Low vs. Higher Pressure
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies